What is the maximum daily dose of Toujeo (insulin glargine U‑300)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Daily Dose of Toujeo Max SoloStar (U-300)

The Toujeo Max SoloStar prefilled pen can deliver up to 160 units in a single injection, and there is no absolute maximum daily dose specified—dosing should be titrated based on individual metabolic needs and glycemic control. 1

Device-Specific Dosing Capabilities

The Toujeo Max SoloStar pen has specific mechanical limitations that define its maximum per-injection capacity:

  • Contains 900 units of insulin glargine U-300 per pen 1
  • Delivers doses in 2-unit increments 1
  • Maximum single injection: 160 units 1
  • Recommended for patients requiring at least 20 units per day 1

Practical Dosing Considerations

While no absolute maximum daily dose exists, clinical context provides guidance:

  • Type 2 diabetes patients typically require approximately 1 unit/kg of body weight daily when insulin resistant 2, 3
  • Patients requiring >200 units/day may be candidates for U-500 regular insulin instead 4
  • U-300 glargine allows higher doses per volume compared to U-100 formulations, making it suitable for patients with significant insulin resistance 4, 5

Dosing Titration Parameters

The FDA label specifies clear titration guidelines:

  • Titrate no more frequently than every 3-4 days to allow full glucose-lowering effect to manifest 1
  • The maximum glucose-lowering effect takes 5 days to fully develop after dose changes 1
  • Monitor glucose daily during initiation and dose adjustments 1

Important Caveats

Unit-for-unit, Toujeo U-300 has lower glucose-lowering efficacy than U-100 glargine, so patients switching from other basal insulins typically require higher total daily doses to achieve equivalent glycemic control 1, 6. This is due to delayed redissolution from the subcutaneous depot, resulting in a flatter, more prolonged pharmacokinetic profile 6.

If a patient requires doses exceeding what can be practically delivered with Toujeo (e.g., consistently needing multiple injections daily to achieve >200-300 units), consider switching to U-500 regular insulin, which is specifically indicated for patients requiring >200 units/day 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.